Potent inhibitor of FLT3 (IC50 = 5 nM, wild-type FLT3) with more potent activity against all FLT3 mutants.1 It also potently inhibits Axl (IC50 = 41 nM). Clinically useful in the treatment of acute myeloid leukemia. Gilteritinib has also been shown to in
* VAT and and shipping costs not included. Errors and price changes excepted